📰 Nuclear Export News
Page 15 - Nuclear Export News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nuclear Export. Real-time updates on events, politics, business and more.
April 28, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...
April 27, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
April 27, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
April 24, 2022
Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) and Inventiva (NASDAQ:IVA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership. Profitability This table compares Karyopharm Therapeutics and Inventiva’s net margins, […]
April 22, 2022
Wall Street analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) to announce sales of $35.14 million for the current quarter, according to Zacks. Six analysts have made estimates for Karyopharm Therapeutics’ earnings. The highest sales estimate is $37.23 million and the lowest is $31.33 million. Karyopharm Therapeutics reported sales of $23.26 million in the […]
April 21, 2022
Four Westminster College students and two faculty members recently attended the annual meeting of the American Society for Biochemistry and Molecular Biology (ASBMB) held April 2-5, 2022 in Philadelphia.
April 12, 2022
Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) had its target price reduced by Canaccord Genuity Group from $20.00 to $10.00 in a research report released on Monday, The Fly reports. Several other equities research analysts have also commented on KPTI. StockNews.com began coverage on shares of Karyopharm Therapeutics in a research report on Thursday, March 31st. […]
April 7, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
April 1, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
March 31, 2022
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) shares traded up 4.2% on Thursday . The stock traded as high as $7.74 and last traded at $7.66. 11,834 shares were traded during mid-day trading, a decline of 100% from the average session volume of 3,780,177 shares. The stock had previously closed at $7.35. Several research analysts […]